- Home
- ATRA vs AVTE Comparison
ATRA vs AVTE Comparison
Compare ATRA & AVTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRA
- AVTE
- Stock Information
- Founded
- ATRA 2012
- AVTE 2018
- Country
- ATRA United States
- AVTE United States
- Employees
- ATRA N/A
- AVTE N/A
- Industry
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- AVTE Biotechnology: Pharmaceutical Preparations
- Sector
- ATRA Health Care
- AVTE Health Care
- Exchange
- ATRA Nasdaq
- AVTE Nasdaq
- Market Cap
- ATRA 39.7M
- AVTE 72.5M
- IPO Year
- ATRA 2014
- AVTE 2021
- Fundamental
- Price
- ATRA $6.86
- AVTE $2.47
- Analyst Decision
- ATRA Buy
- AVTE Hold
- Analyst Count
- ATRA 6
- AVTE 7
- Target Price
- ATRA $25.70
- AVTE $11.75
- AVG Volume (30 Days)
- ATRA 71.1K
- AVTE 91.8K
- Earning Date
- ATRA 03-07-2025
- AVTE 05-12-2025
- Dividend Yield
- ATRA N/A
- AVTE N/A
- EPS Growth
- ATRA N/A
- AVTE N/A
- EPS
- ATRA N/A
- AVTE N/A
- Revenue
- ATRA $128,940,000.00
- AVTE N/A
- Revenue This Year
- ATRA N/A
- AVTE N/A
- Revenue Next Year
- ATRA N/A
- AVTE N/A
- P/E Ratio
- ATRA N/A
- AVTE N/A
- Revenue Growth
- ATRA 1404.02
- AVTE N/A
- 52 Week Low
- ATRA $5.40
- AVTE $1.25
- 52 Week High
- ATRA $20.83
- AVTE $32.42
- Technical
- Relative Strength Index (RSI)
- ATRA 41.62
- AVTE 49.26
- Support Level
- ATRA $5.94
- AVTE $2.45
- Resistance Level
- ATRA $7.02
- AVTE $2.57
- Average True Range (ATR)
- ATRA 0.58
- AVTE 0.08
- MACD
- ATRA 0.07
- AVTE 0.01
- Stochastic Oscillator
- ATRA 52.36
- AVTE 44.44
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About AVTE Aerovate Therapeutics Inc.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.